What is the Latest Update on the Lipitor Diabetes Litigation?
In January 2017, the U.S. District Judge presiding over the Lipitor litigation granted Pfizer’s motion for summary judgment and dismissed all cases. Despite strong evidence in support of these claims, the decision has been upheld on appeal.
New cases are no longer being accepted. This page is maintained for informational purposes only.
Lipitor (atorvastatin) was first introduced in 1996 and generated more than $125 billion in sales for Pfizer before it became available as a generic in 2011.
It is one of the best known brand-name prescription medications in the world and thousands of former users may have developed type 2 diabetes as a result of the cholesterol drug.
A diabetes diagnosis from Lipitor can have a substantial impact on an individual’s overall health and quality of life, resulting in permanent lifestyle changes and increasing the risk of a number of other health problems, including the heart disease the drug was supposed to help prevent.
According to allegations raised in the Lipitor diabetes litigation, Pfizer should be required to compensate users for failing to disclose information about the potential side effects of their medication.
If proper warnings had been provided for consumers and the medical community, thousands of women may have avoided this devastating disease by choosing not to use Lipitor or by monitoring their blood glucose levels to see if the drug was adversely affecting their metabolism.
Lipitor Diabetes Litigation Status
In February 2014, the U.S. Judicial Panel on Multidistrict Litigation (JPML) approved a request to consolidate and centralize all Lipitor diabetes cases pending throughout the federal court system, placing the litigation before U.S. District Judge Richard M. Gergel in the District of South Carolina to reduce duplicative discovery, avoid conflicting pretrial rulings from different judges and to serve the convenience of the parties, witnesses and the courts.
While an MDL is often confused with a Lipitor class action lawsuit, each claim would still remain an individual case. The litigation will not proceed through one class representative, but each plaintiff must still establish that their specific diabetes diagnosis was caused by Lipitor and that Pfizer provided inadequate warnings.
As part of the coordinated pretrial proceedings in the Lipitor MDL, a small group of case were prepared for early trial dates, known as “bellwether” cases, which are designed to help the parties gauge how juries may respond to certain evidence and testimony that will be repeated throughout the litigation.
The first Lipitor trial was scheduled to begin in November 2015. However, the case was dismissed and no claims were allowed to go before a jury in the federal court system.